Newswire (Published: Tuesday, January 24, 2017, Received: Thursday, January 19, 2017, 8:48:13 PM CST)

Word Count: 620

Findings from Institute of Genomic Medicine in Prostate Cancer Provides New Insights (Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news originating from Mexico City, Mexico, by NewsRx correspondents, research stated, "At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the 'gray area' (4-10?ng/ml) are currently subjected to unnecessary biopsy due to overdiagnosis. Certain microRNAs (miRs) have been proven to be useful biomarkers, several of which are detectable in bodily fluids."

Our news journalists obtained a quote from the research from the Institute of Genomic Medicine, "The present study identified and validated a urinary miR-based signature to enhance the specificity of PCa diagnosis and to reduce the number of patients with benign conditions undergoing biopsy. Seventy-three urine samples from Mexican patients with diagnosis of PCa with a Gleason score greater than or equal to7 and 70?patients diagnosed with BPH were collected after digital rectal examination (DRE) of the prostate. miR expression profiles were determined using TaqMan Low Density Array experiments, and normalized Ct values for the miRs were compared between PCa and BPH groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate whether miR detection in urine is suitable for distinguishing patients with PCa from those with BPH. The identified miR-100/200b signature was significantly correlated with PCa. Using a multivariable logistic regression approach, a base model including the clinical variables age, prostate-specific antigen (PSA), the percentage of free PSA and DRE was generated, and a second base model additionally contained the miR-100/200b signature. ROC analysis demonstrated that the combined model significantly outperformed the capacity of PSA (p <0.001) and the base model (p=0.01) to discriminate between PCa and BPH patients. In terms of evaluation of the sub-group of patients in the gray zone of PSA levels, the performance of the combined model for predicting PCa cases was significantly superior to PSA level determination (p <0.001) and the base model (p=0.009). In addition, decision curve analysis demonstrated that the use of the combined model increased the clinical benefit for patients and produced a substantial reduction in unnecessary biopsies across a range of reasonable threshold probabilities (10-50%). Detection of the urinary miR signature identified in the present study as part of clinical diagnostic procedures will enhance the accuracy of PCa diagnosis and provide a clinical benefit for patients with BPH by sparing them from undergoing invasive biopsy."

According to the news editors, the research concluded: "To the best of our knowledge, the present study was the first to describe the profiling of urinary miR100 and miR-200b levels for the clinical diagnosis of PCa."

For more information on this research see: Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Molecular Medicine Reports, 2016;13(6):4549-60 (see also Oncology - Prostate Cancer).

The news correspondents report that additional information may be obtained from A.I. Salido-Guadarrama, Oncogenomics Laboratory, The National Institute of Genomic Medicine, Mexico City 14610, Mexico. Additional authors for this research include J.G. Morales-Montor, C. Rangel-Escareno, E. Langley, O. Peralta-Zaragoza, J.L. Cruz Colin and M. Rodriguez-Dorantes.

Keywords for this news article include: Oncology, Mexico City, Kallikreins, Endopeptidases, Prostate Cancer, Serine Proteases, Peptide Hydrolases, Prostatic Neoplasms, Enzymes and Coenzymes, North and Central America, Diagnostics and Screening, Prostate Specific Antigen.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
Mexico
Americas
México
Mexico City

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer